Examkin

Question

Difficulty: HardPharmacokinetic and Pharmacodynamic Principles

A 2828-year-old man is brought to the emergency department by paramedics after being found unresponsive at home. His respiratory rate is 66 breaths/min, and oxygen saturation is 84%84\% on room air. Physical examination reveals pinpoint pupils and cyanosis of the lips. Paramedics administered a standard 0.40.4 mg intravenous dose of naloxone en route with no clinical improvement. In the emergency department, the patient requires three additional 2.02.0 mg intravenous doses of naloxone before his respiratory rate improves to 1414 breaths/min and he regains consciousness. Review of his electronic medical record reveals that he recently enrolled in an outpatient medication-assisted treatment program for substance use disorder. Which of the following pharmacodynamic characteristics of this patient's most likely maintenance medication best explains the need for unusually high doses of the reversal agent?

  1. High receptor binding affinity with slow dissociation kineticsAnswer
  2. B
    Irreversible covalent binding to the target mu-opioid receptors
  3. C
    Extensive distribution into adipose tissue with a prolonged elimination half-life
  4. D
    Induction of hepatic cytochrome P450 enzymes leading to rapid antidote clearance
  5. E
    Agonist-induced downregulation of mu-opioid receptors requiring higher antidote concentrations

Answer

High receptor binding affinity with slow dissociation kinetics
The correct answer is high receptor binding affinity with slow dissociation kinetics. The patient's presentation of an opioid toxidrome despite enrollment in a substance use treatment program strongly suggests toxicity from buprenorphine, a partial mu-opioid agonist used for medication-assisted treatment. Buprenorphine is unique among opioids due to its exceptionally high binding affinity for the mu-opioid receptor—affinity that exceeds even that of the competitive antagonist naloxone. Additionally, it has very slow receptor dissociation kinetics. Because buprenorphine binds tightly and releases slowly, standard doses of naloxone (e.g., 0.40.4 mg) are often insufficient to competitively displace it from the receptors. Consequently, clinicians must administer significantly higher or repeated doses of naloxone (often up to 1010 mg) to successfully reverse buprenorphine-induced respiratory depression.

Step-by-Step Solution

1
Identify the primary clinical toxidrome and contextual clues.
The patient presents with the classic opioid overdose triad (respiratory depression, pinpoint pupils, CNS depression) and is enrolled in an outpatient treatment program, highly suggesting buprenorphine toxicity.
Recognizing the likely offending agent is required to analyze its specific pharmacological properties.
2
Analyze the atypical response to the standard intervention.
The patient failed to respond to a standard 0.40.4 mg dose of naloxone and required massive doses (total 6.46.4 mg) to achieve respiratory reversal.
This clinical resistance indicates that the offending opioid is exceptionally difficult to displace from the receptor.
3
Correlate the clinical resistance with pharmacodynamic principles.
Buprenorphine has a greater binding affinity for the mu-opioid receptor than naloxone and exhibits slow dissociation kinetics, necessitating much higher concentrations of a competitive antagonist to achieve displacement.
Understanding the difference between pharmacokinetic distribution and pharmacodynamic receptor affinity is essential for selecting the correct mechanism.

Key Concept

Pharmacodynamics of partial agonists and competitive antagonism (Buprenorphine vs. Naloxone).
Estimated Time:2m 0s
Rate this question

Topics

Pharmacokinetic and Pharmacodynamic Principles

More questions from this topic